Navigation Links
BioMotiv Secures $46 Million in Funding
Date:8/5/2013

CLEVELAND, Aug. 5, 2013 /PRNewswire-USNewswire/ -- BioMotiv, a drug development accelerator based in Cleveland, Ohio, today announced that it has increased its total capital from investors to $46 million, adding Nationwide Mutual Insurance Company and several individual investors to its founding investors, University Hospitals of Cleveland and the Harrington Family.  Nationwide Mutual Insurance Company also will appoint a representative to serve on the Board of Managers of BioMotiv. 

(Logo: http://photos.prnewswire.com/prnh/20130805/DC57374LOGO)

"BioMotiv is a new business model for accelerating breakthrough discoveries into medicines, aligning capital and collaborations to develop a portfolio of therapeutics," said Baiju R. Shah, Chief Executive Officer of BioMotiv.  "This support from local institutions and investors provides the company a strong foundation on which to build nationally."

Launched last year, BioMotiv has established its organization and operations and attracted a world-renowned advisory board that includes several former heads of global pharmaceutical research and development organizations to manage a portfolio of promising drug technologies.  The company is affiliated with The Harrington Project for Discovery and Development, a $250 million national initiative initiated by University Hospitals.

"We license early-stage technologies and then develop them with the oversight of our experienced team and network of partners," said Shah.  BioMotiv has begun work on several promising technologies sourced from research institutions and industry sources.

BioMotiv continues to seek additional early-stage therapeutic technologies that are at the pre-clinical or early-clinical stage of development. 

About The Harrington Project

The Harrington Project for Discovery and Development is a $250 million national initiative to support the discovery and development of breakthrough discoveries by physician-scientists.  The Harrington Project, centered at University Hospitals Case Medical Center, is a new and powerful national model that addresses a set of challenges in advancing medicine through its innovative approach.  It includes the Harrington Discovery Institute and BioMotiv. The project, powered by a generous gift and investment from the Harrington family, successful entrepreneurs and recognized philanthropists in Cleveland, provides a comprehensive model to advance discoveries into development and to create novel therapies for patient care.

For more information about the Harrington Discovery Institute, go to: www.uhharringtondiscoveryinstitute.org.

For more information about BioMotiv, go to: www.BioMotiv.com.


'/>"/>
SOURCE BioMotiv
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMotiv Secures $21 million in Initial Funding
2. BioMotiv Names New Chief Executive Officer
3. Stark Medical Secures GSA Schedule Contract, Looks to Supply VA
4. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
5. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
6. SecureState Identifies Top 5 Vulnerabilities Facing Hospitals and Medical Device Manufactures
7. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
8. Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
9. United Spinal Secures Victory in Protecting Access to Complex Rehab Technology in Washington State
10. Alimera Sciences Secures $20 Million Debt Facility
11. Henry Schein Secures $300 Million Of Committed Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):